British Journal of Oral and Maxillofacial Surgery
Volume 47, Issue 8 , Pages 598-601 , December 2009

A survey of consultant members of the British Association of Oral and Maxillofacial Surgeons regarding bisphosphonate-induced osteonecrosis of the jaws

  • S.N. Rogers

      Affiliations

    • Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK
    • Evidence-Based Practice Research Centre (EPRC), Faculty of Health, Edge Hill University, St Helens Road, Ormskirk L39 4QP, UK
    • Corresponding Author InformationCorresponding author at: Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK. Tel.: +44 0151 529 5287; fax: +44 0151 529 5288.
    • ,
  • J. Hung

      Affiliations

    • Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK
    • ,
  • A.J. Barber

      Affiliations

    • Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK
    • ,
  • D. Lowe

      Affiliations

    • Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK
    • Evidence-Based Practice Research Centre (EPRC), Faculty of Health, Edge Hill University, St Helens Road, Ormskirk L39 4QP, UK

,Accepted 27 July 2009.

References 

  1. Cheng A, Mavrokokki A, Carter G, Stein B, Fazzalari NL, Wilson DF, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J. 2005;50(4 Suppl. 2):S4–S13
  2. Marketos M. The top 200 brand drugs in 2003 (by units). Drug Topics. 2004;148:76
  3. National Institute for Clinical Excellence . Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal guidance 87. London: NICE; 2005;
  4. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2008;54:1066–1072
  5. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003;327:469;Erratum in: BMJ 2004; 328:384
  6. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26:5904–5909
  7. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857–869
  8. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol. 2009;112:605–609
  9. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119(Suppl. 2):S150–S162
  10. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117
  11. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534
  12. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–1575
  13. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122(2 Suppl.):S33–45
  14. Novince CM, Ward BB, McCauley LK. Osteonecrosis of the jaw: an update and review of recommendations. Cells Tissues Organs. 2009;189:275–283
  15. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–836
  16. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415–423
  17. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009;140:61–66
  18. Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008;35:1391–1397Erratum in: J Rheumatol 2008; 35:1688. J Rheumatol 2008; 35:2084
  19. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369–376
  20. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J. 2009;206:93–98
  21. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, et al. “Bis-phossy jaws” - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2008;36:95–103
  22. Grewal VS, Fayans EP. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management. NY State Dent J. 2008;74:38–44
  23. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009;60:85–96
  24. McLeod MN, Bater MC, Brennan PA. Management of patients at risk of osteoradionecrosis: questionnaire survey of practice in the United Kingdom, and suggestions for best practice. Br J Oral Maxillofac Surg 2009 Aug 4, [Epub ahead of print].

PII: S0266-4356(09)00483-5

doi: 10.1016/j.bjoms.2009.07.020

British Journal of Oral and Maxillofacial Surgery
Volume 47, Issue 8 , Pages 598-601 , December 2009

Article Tools